Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Luetkemeyer, Anne F., Rosenkranz, Susan L., Lu, Darlene, Grinsztejn, Beatriz, Sanchez, Jorge, Ssemmanda, Michael, Sanne, Ian, McIlleron, Helen, Havlir, Diane V., Haas, David W.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
HIV/AIDS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542662/
https://ncbi.nlm.nih.gov/pubmed/25722197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ155
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados